Literature DB >> 24337852

Effects of Chinese Fructus Mume formula and its separated prescription extract on insulin resistance in type 2 diabetic rats.

Jing-Bin Li1, Li-Jun Xu1, Hui Dong1, Zhao-Yi Huang1, Yan Zhao1, Guang Chen2, Fu-Er Lu3.   

Abstract

The effect of Fructus Mume formula and its separated prescription extract on insulin resistance in type 2 diabetic rats was investigated. The rat model of type 2 diabetes was established by feeding on a high-fat diet for 8 weeks and by subsequently intravenous injection of small doses of streptozotocin. Rats in treatment groups, including the Fructus Mume formula treatment group (FM), the cold property herbs of Fructus Mume formula treatment group (CFM), the warm property herbs of Fructus Mume formula treatment group (WFM), were administrated with Fructus Mume formula and its separated prescription extract by gavage, while the rats in diabetic model group (DM) and metformin group (MET) were given by gavage with normal saline and metformin correspondingly. The body weight before and after treatment was measured, and the oral glucose tolerance test (OGTT) and the insulin release test (IRT) were performed. The homeostasis model assessment-insulin resistance index (HOMA-IR) was calculated. The protein and mRNA expression levels of Insr, β-arrestin-2, Irs-1 and Glut-4 in the liver, skeletal muscle and fat tissues were detected by using Western blotting and RT-PCR respectively. The results demonstrated that, as compared with DM group, OGTT, IRT (0 h, 1 h) levels and HOMR-IR in treatment groups were all reduced, meanwhile their protein and mRNA expression levels of Insr, Irs-1 and Glut-4 in the liver, skeletal muscle and fat tissues were obviously increased, and their protein and mRNA expression levels of β-arrestin-2 in the liver and skeletal muscle tissues were also markedly increased. It was suggested that the Fructus Mume formula and its separated prescription extracts could effectively improve insulin resistance in type 2 diabetic rats, which might be related to the up-regulated expression of Insr, Irs-1 and Glut-4 in the liver, skeletal muscle and fat tissues, and β-arrestin-2 in the liver and skeletal muscle tissues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337852     DOI: 10.1007/s11596-013-1215-7

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  28 in total

1.  [Study of xixin, duzhong and mixture to the antioxidant system of D-galactose-induced senile mice].

Authors:  K Li; M Liu; X Wei
Journal:  Zhong Yao Cai       Date:  2000-03

2.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 3.  Molecular mechanisms of insulin resistance in diabetes.

Authors:  Kouidhi Soumaya
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  [Study on fingerprints of chemical constituents of cinnamomi ramulus and cinnamomi cortex].

Authors:  Peng-fei Yuan; Ming-ying Shang; Shao-qing Cai
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2012-10

5.  Effects of Radix aconiti lateralis preparata and Rhizoma zingiberis on energy metabolism and expression of the genes related to metabolism in rats.

Authors:  Hua-Yun Yu; Shi-Jun Wang; Jia-Lin Teng; Xu-Ming Ji; Zhi-Chun Wu; Qing-Cui Ma; Xian-Jun Fu
Journal:  Chin J Integr Med       Date:  2012-01-10       Impact factor: 1.978

6.  Ginsenoside Rg1 promotes glucose uptake through activated AMPK pathway in insulin-resistant muscle cells.

Authors:  Hye-Min Lee; Ok-Hwan Lee; Kui-Jin Kim; Boo-Yong Lee
Journal:  Phytother Res       Date:  2011-12-15       Impact factor: 5.878

7.  Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF.

Authors:  Gregory A Moy; Ewan C McNay
Journal:  Physiol Behav       Date:  2012-12-06

8.  Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome.

Authors:  A Kotronen; A Seppälä-Lindroos; R Bergholm; H Yki-Järvinen
Journal:  Diabetologia       Date:  2007-11-16       Impact factor: 10.122

Review 9.  Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction.

Authors:  Rive Sarfstein; Haim Werner
Journal:  Endocrinology       Date:  2013-03-18       Impact factor: 4.736

10.  Fructus mume formula in the treatment of type 2 diabetes mellitus: a randomized controlled pilot trial.

Authors:  Xiang Tu; Chunguang Xie; Fei Wang; Qiu Chen; Zhihuang Zuo; Qiong Zhang; Xingshuan Wang; Sen Zhong; James B Jordan
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-07       Impact factor: 2.629

View more
  4 in total

1.  Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.

Authors:  Shu-Jun Jiang; Hui Dong; Jing-Bin Li; Li-Jun Xu; Xin Zou; Kai-Fu Wang; Fu-Er Lu; Ping Yi
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Tang-Nai-Kang alleviates pre-diabetes and metabolic disorders and induces a gene expression switch toward fatty acid oxidation in SHR.Cg-Leprcp/NDmcr rats.

Authors:  Linyi Li; Hisae Yoshitomi; Ying Wei; Lingling Qin; Jingxin Zhou; Tunhai Xu; Xinli Wu; Tian Zhou; Wen Sun; Xiangyu Guo; Lili Wu; Haiyan Wang; Yan Zhang; Chunna Li; Tonghua Liu; Ming Gao
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

3.  Wu-Mei-Wan Reduces Insulin Resistance via Inhibition of NLRP3 Inflammasome Activation in HepG2 Cells.

Authors:  Xueping Yang; Lingli Li; Ke Fang; Ruolan Dong; Jingbin Li; Yan Zhao; Hui Dong; Ping Yi; Zhaoyi Huang; Guang Chen; Fuer Lu
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-27       Impact factor: 2.629

4.  Wu-Mei-wan protects pancreatic β cells by inhibiting NLRP3 Inflammasome activation in diabetic mice.

Authors:  Xueping Yang; Fuer Lu; Lingli Li; Jingbin Li; Jinlong Luo; Siyi Zhang; Xinqiao Liu; Guang Chen
Journal:  BMC Complement Altern Med       Date:  2019-01-31       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.